PowerPlex® ESX 17 System for Use on the Spectrum Compact CE System Technical Manual
Instructions for Use of Product(s)
DC6720
Literature # TMD063
The PowerPlex® ESX 17 System is used for human identification applications including forensic analysis, relationship testing and research use. This system allows co-amplification and fourcolor fluorescent detection of seventeen loci (sixteen STR loci and Amelogenin), includingD18S51, D21S11, TH01, D3S1358, Amelogenin, D16S539, D2S1338, D1S1656, D10S1248,
FGA, D8S1179, vWA, D22S1045, SE33, D19S433, D12S391 and D2S441.
The PowerPlex® ESX 17 System amplifies the loci recommended by the European Network of Forensic Science Institutes (ENFSI) and European DNA Profiling Group (EDNAP) as mini-STRs (<125bp; D2S441, D10S1248 and D22S1045) or midi-STRs (125–185bp; D1S1656 and D12S391). To complement this design and allow maximal recovery of allelic information from degraded samples, the PowerPlex® ESI 17 Pro System, which amplifies the same seventeen loci present in the PowerPlex® ESX 17 System, is designed to amplify six of the original seven European Standard Set (ESS) loci (D3S1358, D18S51, TH01, vWA, D8S1179 and the more common FGA alleles) along with D16S539 and D19S433 as smaller amplicons (<250bp), while the new ENFSI/EDNAP loci are present as larger amplicons. Therefore, these two STR systems can be used to complement each other when analyzing degraded or challenging samples to maximize recovery of allelic information from as many loci as possible and also allow confirmation of results obtained with the other system.
The PowerPlex® ESX 17 System provides all materials to amplify STR regions of human genomic DNA, including hot-start Taq DNA polymerase, which is a component of the PowerPlex® ESX 5X Master Mix. This manual contains a protocol to separate amplified products and detect separated material on the Spectrum Compact CE System.
Summary of Changes
The following changes were made to the 9/21 revision of this document:
- Expanded character rules table in Section 5.3.
- Updated disclaimers.
Revised 9/21.